Recently, the Vunakizumab Injection (trade name: 安达静) of Suzhou Suncadia Biopharmaceuticals Co., Ltd. is approved by China NMPA. It is indicated for the treatment of adult patients with moderate-to-severe plaque psoriasis through systematic treatment or phototherapy.

The Vunakizumab Injection is a recombinant humanised IgG1 subtype anti-interleukin-17A (IL-17A) monoclonal antibody that inhibits the onset and progression of inflammation by specifically binding to IL-17A protein in serum and blocking the binding of IL-17A to IL-17RA (IL-17A receptor).

The marketing of this product provides a new treatment option for adult patients with plaque psoriasis.